#Moln hashtag - Bluesky

1 week ago

Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes Molecular Partners AG

#MOLN Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability to Multiple Isotopes

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Ovarian and lung cancer in focus as Molecular Partners heads to AACR 2026 Ovarian cancer, bioinformatics-guided immunotherapy and MP0712 Radio-DARPin for anti-DLL3 small cell lung cancer feature in Molecular Partners' AACR 2026 posters.

#MOLN Molecular Partners to Hold Three Poster Presentations at AACR 2026

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

2 weeks ago

Molecular Partners Reports Highlights and Financial Results for Full Year 2025 Initiated US Phase 1/2a study of DLL3-targeting 212 Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026 Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging;

#MOLN Molecular Partners Reports Highlights and Financial Results for Full Year 2025

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results Molecular Partners (SIX: MOLN; NASDAQ: MOLN) announced CEO Patrick Amstutz will present at two investor conferences in March 2026 and that the company will release its full-year 2025 financial results and Annual Report on March 12, 2026.Fireside chats at TD Cowen (March 2) and Leerink Partners (March 9) will be available on the company investor website. The results release is scheduled for March 12 at 4:00 pm EDT (9:00 pm CET).

#MOLN Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics Molecular Partners (SIX: MOLN; NASDAQ: MOLN) signed a non-exclusive development agreement with Eckert & Ziegler to advance its Radio-DARPin pipeline using alpha and beta emitters.The collaboration covers development and manufacturing support for Actinium-225 (225Ac) and Lutetium-177 (177Lu), leveraging Eckert & Ziegler’s Alpha Laboratory in Berlin. The company plans to present pre-clinical multi-isotope data at a March 2026 summit and notes its lead candidate MP0712 recently opened a Phase 1/2a trial in small cell lung cancer.

#MOLN Molecular Partners Signs Development Agreement with Eckert & Ziegler for Targeted Alpha Radiotherapeutics

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Minnesota's Nursing Leaders Collaborate with Virtual Nursing Academy to Enhance Virtual Care The Minnesota Organization of Leaders in Nursing has partnered with the Virtual Nursing Academy to enhance nursing leadership in virtual care across the state.

Minnesota's Nursing Leaders Collaborate with Virtual Nursing Academy to Enhance Virtual Care #United_States #Minneapolis #Virtual_Care #Nursing_Academy #MOLN

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026 Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026 Phase 2 investigator-initiated trial of MP0317 now open with patient

#MOLN Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting Molecular Partners (NASDAQ: MOLN) presented updated Phase 1/2a data for tetra-specific T-cell engager MP0533 in relapsed/refractory AML at ASH on December 7, 2025. As of the September 1, 2025 cut-off, 54 patients received MP0533 and 8 of 48 evaluable patients responded (5 composite complete responses and 3 MLFS). Densified and higher-frequency dosing (cohorts 8–9) was tolerable, increased serum exposure in cycle 1, and showed preliminary antitumor activity. Responses clustered in patients with

#MOLN Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

Carl Gylling

@carlgylling.bsky.social

4 months ago

Det är lite fascinerande att se lågt gående moln passera under högre moln. Då blir man mer medveten om att himlen är tredimensionell och inte bara en bakgrundsbild till världen. #väder #natur #moln

0 0 0 0

サードニュース@相互フォロー100%

@new3rd.bsky.social

4 months ago

新サイズ「Medium」登場！molnの魅力的なスーツケースをチェック franky株式会社が新たに展開する旅を意識したスーツケース「Medium」をご紹介。機能美とデザインが融合した厳選の3色をぜひご覧ください。

新サイズ「Medium」登場！molnの魅力的なスーツケースをチェック #東京都 #渋谷区 #スーツケース #moln #franky株式会社

franky株式会社が新たに展開する旅を意識したスーツケース「Medium」をご紹介。機能美とデザインが融合した厳選の3色をぜひご覧ください。

0 0 0 0

Market Wire News

@marketwirenews.com

4 months ago

Breaking News: ( NASDAQ: #MOLN ) Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action Molecular Partners (NASDAQ: MOLN) presented new human imaging and mechanism data for MP0712, a DLL3-targeting Radio-DARPin, at TRP Summit Europe on Nov 12, 2025. A named‑patient case from South Africa showed specific tumor uptake at 24 hours and sustained signal over 4 days using 203Pb imaging, with limited kidney and liver exposure. The company filed a Phase 1 IND for MP0712 and expects to initiate the US trial by end‑2025, with initial clinical data anticipated in 2026. Presentation and webcast details were provided for Nov 12, 2025.

#MOLN Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025 Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced significant tumor regression in vivo

#MOLN Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs

#MOLN Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

Lars Sjögreen

@barse.bsky.social

7 months ago

Clouds

#acrylicpainting #landscape #clouds #akrylmålning #akryl #acrylic #goldenacrylics #moln

11 0 0 0

StockTitan

@stocktitan.net

7 months ago

Breakthrough AML Treatment Shows 30% Response Rate: Molecular Partners' MP0533 Achieves 6-Month Durability Biotech's MP0533 achieves complete responses in relapsed/refractory AML patients. Cash position of CHF 114M extends runway to 2028. IND filing for radio-DARPin MP0712 expected Q3 2025.

#MOLN Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

Annika Brodin

@annikabrodin.bsky.social

7 months ago

Clouds.
Thunder on the way.
#moln #clouds #åska #thunder

3 1 0 0

StockTitan

@stocktitan.net

9 months ago

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 Molecular Partners (NASDAQ: MOLN) and Orano Med announced preclinical data for MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, at SNMMI 2025. The data showed MP0726 demonstrates high affinity and selective binding to membrane-bound MSLN, with favorable biodistribution in tumor models showing up to 34% tumor accumulation at 24 hours post-injection and a tumor-to-kidney ratio of 4.5. This represents the company's second Radio-DARPin program, with the first program MP0712 (targeting DLL3) expected to begin Phase 1 trials in H2 2025. The collaboration leverages Orano Med's expertise in targeted alpha-particle therapies with 212Pb and Molecular Partners' DARPin technology to address the challenge of shed MSLN acting as a decoy receptor in cancer treatment.

#MOLN Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 Molecular Partners (NASDAQ: MOLN) announced positive Phase 1/2a trial data for MP0533, their tetraspecific T-cell engager for relapsed/refractory acute myeloid leukemia (AML), at EHA 2025. In cohort 8, 3 out of 8 evaluable patients (>30%) achieved clinical responses after the first cycle, with one patient maintaining response beyond 6 months. The trial implemented an accelerated step-up dosing regimen, reaching target dose by day 12 instead of day 15, resulting in longer therapeutic exposure. Five out of 8 patients showed >50% blast reduction, with MP0533 demonstrating an acceptable safety profile. Based on these encouraging results, cohort 9 is now ongoing with further optimized dosing, and initial data is expected in H2 2025. Future study cohorts will evaluate MP0533 in combination with azacitidine/venetoclax.

#MOLN Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

www.stocktitan.net/news/MOLN/molecular-part...

0 0 0 0